Please assess the completion status of the following clinical trial:

Trial Title: OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic or unresectable clear cell kidney cancer confirmed by biopsy~* Previous nephrectomy~* Maximum of 1 previous regimen for metastatic disease~* Ability to perform activities of daily living with minimal assistance~* Measurable disease~* Adequate bone marrow, liver and kidney function~* Give written informed consent prior to study entry~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Treatment with more than one previous regimen for metastatic disease~* Clinically significant cardiovascular disease~* Active brain metastases~* History of CNS disease~* Clinical history of coughing or vomiting blood.~* History of thromboembolic disease.~* PEG or G-tube are ineligible.~* Current use of full dose anticoagulants or thrombolytic agents~* Chronic daily treatment with aspirin or NSAIDS~* Any clinical evidence or history of a bleeding or clotting disorder~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OSI-774 & bevacizumab (Type: EXPERIMENTAL): OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).